Published in Arch Gen Psychiatry on February 01, 2007
Brain structural and functional abnormalities in mood disorders: implications for neurocircuitry models of depression. Brain Struct Funct (2008) 6.32
Neurocircuitry of mood disorders. Neuropsychopharmacology (2010) 5.57
Reconsidering anhedonia in depression: lessons from translational neuroscience. Neurosci Biobehav Rev (2010) 3.46
Towards a glutamate hypothesis of depression: an emerging frontier of neuropsychopharmacology for mood disorders. Neuropharmacology (2011) 2.79
Magnetic resonance spectroscopy studies of glutamate-related abnormalities in mood disorders. Biol Psychiatry (2010) 2.08
In vivo magnetic resonance spectroscopy of GABA: a methodological review. Prog Nucl Magn Reson Spectrosc (2011) 1.91
Ketamine and the next generation of antidepressants with a rapid onset of action. Pharmacol Ther (2009) 1.90
The GABAergic deficit hypothesis of major depressive disorder. Mol Psychiatry (2010) 1.80
Global brain gene expression analysis links glutamatergic and GABAergic alterations to suicide and major depression. PLoS One (2009) 1.78
Patient classification as an outlier detection problem: an application of the One-Class Support Vector Machine. Neuroimage (2011) 1.69
Abnormal glutamatergic neurotransmission and neuronal-glial interactions in acute mania. Biol Psychiatry (2008) 1.58
Reduced levels of NR2A and NR2B subunits of NMDA receptor and PSD-95 in the prefrontal cortex in major depression. Prog Neuropsychopharmacol Biol Psychiatry (2008) 1.54
Glutamatergic and resting-state functional connectivity correlates of severity in major depression - the role of pregenual anterior cingulate cortex and anterior insula. Front Syst Neurosci (2010) 1.54
Pathophysiology of depression: do we have any solid evidence of interest to clinicians? World Psychiatry (2010) 1.50
Neurobiological mechanisms in major depressive disorder. CMAJ (2009) 1.49
13C MRS studies of neuroenergetics and neurotransmitter cycling in humans. NMR Biomed (2011) 1.47
Prefrontal cortical GABA abnormalities are associated with reduced hippocampal volume in major depressive disorder. Eur Neuropsychopharmacol (2015) 1.45
Amino acid neurotransmitters assessed by proton magnetic resonance spectroscopy: relationship to treatment resistance in major depressive disorder. Biol Psychiatry (2008) 1.42
Glutamatergic modulators: the future of treating mood disorders? Harv Rev Psychiatry (2010) 1.42
In vivo detection of GABA and glutamate with MEGA-PRESS: reproducibility and gender effects. J Magn Reson Imaging (2011) 1.36
Reduced metabotropic glutamate receptor 5 density in major depression determined by [(11)C]ABP688 PET and postmortem study. Am J Psychiatry (2011) 1.34
In vivo measurements of glutamate, GABA, and NAAG in schizophrenia. Schizophr Bull (2012) 1.28
Stress impairs GABAergic network function in the hippocampus by activating nongenomic glucocorticoid receptors and affecting the integrity of the parvalbumin-expressing neuronal network. Neuropsychopharmacology (2010) 1.27
Astrocyte pathology in major depressive disorder: insights from human postmortem brain tissue. Curr Drug Targets (2013) 1.26
Novel glutamatergic agents for major depressive disorder and bipolar disorder. Pharmacol Biochem Behav (2011) 1.24
Striatum-based circuitry of adolescent depression and anhedonia. J Am Acad Child Adolesc Psychiatry (2013) 1.24
Anterior cingulate cortex γ-aminobutyric acid in depressed adolescents: relationship to anhedonia. Arch Gen Psychiatry (2011) 1.23
A mechanism for value-guided choice based on the excitation-inhibition balance in prefrontal cortex. Nat Neurosci (2012) 1.21
Effect of acamprosate on magnetic resonance spectroscopy measures of central glutamate in detoxified alcohol-dependent individuals: a randomized controlled experimental medicine study. Arch Gen Psychiatry (2010) 1.21
Reduced brain GABA in primary insomnia: preliminary data from 4T proton magnetic resonance spectroscopy (1H-MRS). Sleep (2008) 1.18
Targeting the glutamatergic system to treat major depressive disorder: rationale and progress to date. Drugs (2012) 1.17
Fetal alcohol spectrum disorder-associated depression: evidence for reductions in the levels of brain-derived neurotrophic factor in a mouse model. Pharmacol Biochem Behav (2008) 1.14
Increased ventricular lactate in chronic fatigue syndrome. III. Relationships to cortical glutathione and clinical symptoms implicate oxidative stress in disorder pathophysiology. NMR Biomed (2012) 1.14
The role of the tripartite glutamatergic synapse in the pathophysiology and therapeutics of mood disorders. Neuroscientist (2009) 1.13
Reduced density of calbindin immunoreactive GABAergic neurons in the occipital cortex in major depression: relevance to neuroimaging studies. Biol Psychiatry (2009) 1.10
Human biomarkers of rapid antidepressant effects. Biol Psychiatry (2013) 1.09
Combined neuroimaging, neurocognitive and psychiatric factors to predict alcohol consumption following treatment for alcohol dependence. Alcohol Alcohol (2008) 1.06
Glial and glutamatergic markers in depression, alcoholism, and their comorbidity. J Affect Disord (2010) 1.06
Reduced level of glutamic acid decarboxylase-67 kDa in the prefrontal cortex in major depression. Int J Neuropsychopharmacol (2009) 1.05
Long-lasting antidepressant action of ketamine, but not glycogen synthase kinase-3 inhibitor SB216763, in the chronic mild stress model of mice. PLoS One (2013) 1.04
Accuracy and stability of measuring GABA, glutamate, and glutamine by proton magnetic resonance spectroscopy: a phantom study at 4 Tesla. J Magn Reson (2010) 1.04
Investigation of cortical glutamate-glutamine and γ-aminobutyric acid in obsessive-compulsive disorder by proton magnetic resonance spectroscopy. Neuropsychopharmacology (2012) 1.04
Research applications of magnetic resonance spectroscopy to investigate psychiatric disorders. Top Magn Reson Imaging (2008) 1.03
The impact of gabapentin administration on brain GABA and glutamate concentrations: a 7T ¹H-MRS study. Neuropsychopharmacology (2012) 1.03
Elevated levels of NR2A and PSD-95 in the lateral amygdala in depression. Int J Neuropsychopharmacol (2008) 1.03
Prefrontal cortical gamma-aminobutyric Acid levels in panic disorder determined by proton magnetic resonance spectroscopy. Biol Psychiatry (2008) 1.03
Genetic modulation of GABA levels in the anterior cingulate cortex by GAD1 and COMT. Neuropsychopharmacology (2010) 1.02
Effect of acute psychological stress on prefrontal GABA concentration determined by proton magnetic resonance spectroscopy. Am J Psychiatry (2010) 1.02
Lack of effect of ketamine on cortical glutamate and glutamine in healthy volunteers: a proton magnetic resonance spectroscopy study. J Psychopharmacol (2011) 1.02
Remodeling of axo-spinous synapses in the pathophysiology and treatment of depression. Neuroscience (2012) 0.99
Reduced γ-aminobutyric acid in occipital and anterior cingulate cortices in primary insomnia: a link to major depressive disorder? Neuropsychopharmacology (2012) 0.99
Glutamate and its receptors in the pathophysiology and treatment of major depressive disorder. J Neural Transm (Vienna) (2013) 0.98
Lower glutamic acid decarboxylase 65-kDa isoform messenger RNA and protein levels in the prefrontal cortex in schizoaffective disorder but not schizophrenia. Biol Psychiatry (2014) 0.98
Self-esteem, negative emotionality, and depression as a common temperamental core: a study of mid-adolescent twin girls. J Pers (2009) 0.98
Elevated level of metabotropic glutamate receptor 2/3 in the prefrontal cortex in major depression. Prog Neuropsychopharmacol Biol Psychiatry (2009) 0.97
Emotional memory impairments in a genetic rat model of depression: involvement of 5-HT/MEK/Arc signaling in restoration. Mol Psychiatry (2011) 0.97
An investigation of amino-acid neurotransmitters as potential predictors of clinical improvement to ketamine in depression. Int J Neuropsychopharmacol (2011) 0.97
Glutamate concentration in the medial prefrontal cortex predicts resting-state cortical-subcortical functional connectivity in humans. PLoS One (2013) 0.96
Opposing effects of acute versus chronic blockade of frontal cortex somatostatin-positive inhibitory neurons on behavioral emotionality in mice. Neuropsychopharmacology (2014) 0.96
Antagonist but not agonist labeling of serotonin-1A receptors is decreased in major depressive disorder. J Psychiatr Res (2009) 0.95
Adaptation of brain glutamate plus glutamine during abstinence from chronic methamphetamine use. J Neuroimmune Pharmacol (2008) 0.94
Structural organization of long-range GABAergic projection system of the hippocampus. Front Neuroanat (2009) 0.94
Clinical application of brain imaging for the diagnosis of mood disorders: the current state of play. Mol Psychiatry (2013) 0.93
Normal glutamate but elevated myo-inositol in anterior cingulate cortex in recovered depressed patients. J Affect Disord (2009) 0.91
Regulation of astrocyte glutamine synthetase in epilepsy. Neurochem Int (2013) 0.90
A pilot in vivo proton magnetic resonance spectroscopy study of amino acid neurotransmitter response to ketamine treatment of major depressive disorder. Mol Psychiatry (2015) 0.90
Reduced parahippocampal and lateral temporal GABAA-[11C]flumazenil binding in major depression: preliminary results. Eur J Nucl Med Mol Imaging (2009) 0.90
Genetic association of ErbB4 and human cortical GABA levels in vivo. J Neurosci (2011) 0.88
Association of the GABRD gene and childhood-onset mood disorders. Genes Brain Behav (2010) 0.88
Increased glutamate levels in the medial prefrontal cortex in patients with postpartum depression. Neuropsychopharmacology (2012) 0.87
Two-dimensional J-resolved proton MR spectroscopy and prior knowledge fitting (ProFit) in the frontal and parietal lobes of healthy volunteers: assessment of metabolite discrimination and general reproducibility. J Magn Reson Imaging (2012) 0.86
Bidirectional Homeostatic Regulation of a Depression-Related Brain State by Gamma-Aminobutyric Acidergic Deficits and Ketamine Treatment. Biol Psychiatry (2016) 0.86
A 12-month naturalistic observation of three patients receiving repeat intravenous ketamine infusions for their treatment-resistant depression. J Affect Disord (2012) 0.86
GABAergic control of depression-related brain states. Adv Pharmacol (2015) 0.86
Regional difference in GABA levels between medial prefrontal and occipital cortices. J Magn Reson Imaging (2013) 0.85
The role of glutamate and its receptors in autism and the use of glutamate receptor antagonists in treatment. J Neural Transm (Vienna) (2014) 0.85
Neurochemistry of major depression: a study using magnetic resonance spectroscopy. Psychopharmacology (Berl) (2014) 0.84
Too much of a good thing: blocking noradrenergic facilitation in medial prefrontal cortex prevents the detrimental effects of chronic stress on cognition. Neuropsychopharmacology (2012) 0.84
Why are cortical GABA neurons relevant to internal focus in depression? A cross-level model linking cellular, biochemical and neural network findings. Mol Psychiatry (2014) 0.84
Genetic ablation of the GluK4 kainate receptor subunit causes anxiolytic and antidepressant-like behavior in mice. Behav Brain Res (2011) 0.84
Biological substrates underpinning diagnosis of major depression. Int J Neuropsychopharmacol (2013) 0.84
Maternal immune activation leads to selective functional deficits in offspring parvalbumin interneurons. Mol Psychiatry (2016) 0.84
Differential levels of brain amino acids in rat models presenting learned helplessness or non-learned helplessness. Psychopharmacology (Berl) (2013) 0.83
Lack of effect of citalopram on magnetic resonance spectroscopy measures of glutamate and glutamine in frontal cortex of healthy volunteers. J Psychopharmacol (2009) 0.83
Electroconvulsive Treatment: Hypotheses about Mechanisms of Action. Front Psychiatry (2013) 0.83
Altered γ-aminobutyric acid neurotransmission in major depressive disorder: a critical review of the supporting evidence and the influence of serotonergic antidepressants. Drug Des Devel Ther (2015) 0.83
Magnetic resonance spectroscopy in the evaluation of treatment efficacy in unipolar major depressive disorder: a review of the literature. Funct Neurol (2012) 0.83
The long-lasting antidepressant effects of rapastinel (GLYX-13) are associated with a metaplasticity process in the medial prefrontal cortex and hippocampus. Neuroscience (2015) 0.82
Risk of psychiatric disorders following trigeminal neuralgia: a nationwide population-based retrospective cohort study. J Headache Pain (2015) 0.82
A brief history of the development of antidepressant drugs: from monoamines to glutamate. Exp Clin Psychopharmacol (2015) 0.82
Glutamine deficiency in the prefrontal cortex increases depressive-like behaviours in male mice. J Psychiatry Neurosci (2013) 0.82
Biochemical abnormalities of the medial temporal lobe and medial prefrontal cortex in late-life depression. Psychiatry Res (2009) 0.82
GABAA receptor-acting neurosteroids: a role in the development and regulation of the stress response. Front Neuroendocrinol (2014) 0.82
Effects of fat on MR-measured metabolite signal strengths: implications for in vivo MRS studies of the human brain. NMR Biomed (2013) 0.82
Molecular Mechanism for Stress-Induced Depression Assessed by Sequencing miRNA and mRNA in Medial Prefrontal Cortex. PLoS One (2016) 0.81
Impaired GABA synthesis, uptake and release are associated with depression-like behaviors induced by chronic mild stress. Transl Psychiatry (2016) 0.81
Defects in dendrite and spine maturation and synaptogenesis associated with an anxious-depressive-like phenotype of GABAA receptor-deficient mice. Neuropharmacology (2014) 0.81
Decreased occipital cortical glutamate levels in response to successful cognitive-behavioral therapy and pharmacotherapy for major depressive disorder. Psychother Psychosom (2014) 0.81
Antidepressant-like cognitive and behavioral effects of acute ketamine administration associated with plasticity in the ventral hippocampus to medial prefrontal cortex pathway. Psychopharmacology (Berl) (2015) 0.81
Disinhibition of somatostatin-positive GABAergic interneurons results in an anxiolytic and antidepressant-like brain state. Mol Psychiatry (2016) 0.81
Neurobiology of emotion perception I: The neural basis of normal emotion perception. Biol Psychiatry (2003) 6.93
Neurobiology of emotion perception II: Implications for major psychiatric disorders. Biol Psychiatry (2003) 6.52
Neurocircuitry of mood disorders. Neuropsychopharmacology (2010) 5.57
Discovering endophenotypes for major depression. Neuropsychopharmacology (2004) 4.90
Identification of common variants associated with human hippocampal and intracranial volumes. Nat Genet (2012) 3.73
Neural circuits underlying the pathophysiology of mood disorders. Trends Cogn Sci (2011) 2.76
Antidepressant efficacy of the antimuscarinic drug scopolamine: a randomized, placebo-controlled clinical trial. Arch Gen Psychiatry (2006) 2.68
Bipolar and major depressive disorder: neuroimaging the developmental-degenerative divide. Neurosci Biobehav Rev (2009) 2.44
Choosing the lesser of two evils, the better of two goods: specifying the roles of ventromedial prefrontal cortex and dorsal anterior cingulate in object choice. J Neurosci (2006) 2.40
Toward constructing an endophenotype strategy for bipolar disorders. Biol Psychiatry (2006) 2.09
Differential effects of 5-HTTLPR genotypes on the behavioral and neural responses to tryptophan depletion in patients with major depression and controls. Arch Gen Psychiatry (2006) 2.09
Tryptophan depletion alters the decision-making of healthy volunteers through altered processing of reward cues. Neuropsychopharmacology (2003) 1.99
5-HT(1A) receptor function in major depressive disorder. Prog Neurobiol (2009) 1.99
Response to emotional expressions in generalized social phobia and generalized anxiety disorder: evidence for separate disorders. Am J Psychiatry (2008) 1.99
Volumetric reduction in left subgenual prefrontal cortex in early onset depression. Biol Psychiatry (2002) 1.94
Relationship between amygdala responses to masked faces and mood state and treatment in major depressive disorder. Arch Gen Psychiatry (2010) 1.94
Neural and behavioral responses to tryptophan depletion in unmedicated patients with remitted major depressive disorder and controls. Arch Gen Psychiatry (2004) 1.92
Low glial numbers in the amygdala in major depressive disorder. Biol Psychiatry (2002) 1.86
Downregulation of brain phosphodiesterase type IV measured with 11C-(R)-rolipram positron emission tomography in major depressive disorder. Biol Psychiatry (2012) 1.85
Serotonin 1A receptor reductions in postpartum depression: a positron emission tomography study. Fertil Steril (2007) 1.82
Glial reduction in amygdala in major depressive disorder is due to oligodendrocytes. Biol Psychiatry (2004) 1.82
Nrf2 signaling and cell survival. Toxicol Appl Pharmacol (2009) 1.72
Anterior cingulate desynchronization and functional connectivity with the amygdala during a working memory task predict rapid antidepressant response to ketamine. Neuropsychopharmacology (2010) 1.65
Neural and behavioral substrates of mood and mood regulation. Biol Psychiatry (2002) 1.65
Reduced serotonin type 1A receptor binding in panic disorder. J Neurosci (2004) 1.61
Frontotemporal alterations in pediatric bipolar disorder: results of a voxel-based morphometry study. Arch Gen Psychiatry (2005) 1.57
Cortical abnormalities in bipolar disorder investigated with MRI and voxel-based morphometry. Neuroimage (2005) 1.57
Small nucleolar RNA signatures as biomarkers for non-small-cell lung cancer. Mol Cancer (2010) 1.56
Ventral striatum response during reward and punishment reversal learning in unmedicated major depressive disorder. Am J Psychiatry (2012) 1.55
Reduced hippocampal volume in unmedicated, remitted patients with major depression versus control subjects. Biol Psychiatry (2005) 1.51
The effects of tryptophan depletion on neural responses to emotional words in remitted depression. Biol Psychiatry (2009) 1.50
Self-regulation of amygdala activation using real-time FMRI neurofeedback. PLoS One (2011) 1.50
Mood-congruent bias in affective go/no-go performance of unmedicated patients with major depressive disorder. Am J Psychiatry (2005) 1.48
Neural response to catecholamine depletion in unmedicated subjects with major depressive disorder in remission and healthy subjects. Arch Gen Psychiatry (2008) 1.42
Multivoxel MR spectroscopy in acute ischemic stroke: comparison to the stroke protocol MRI. Stroke (2012) 1.41
Match between cue and memory valence during autobiographical memory recall in depression. Psychol Rep (2012) 1.40
Elevated serotonin transporter binding in major depressive disorder assessed using positron emission tomography and [11C]DASB; comparison with bipolar disorder. Biol Psychiatry (2007) 1.40
Cerebral blood flow in immediate and sustained anxiety. J Neurosci (2007) 1.38
Neural basis of abnormal response to negative feedback in unmedicated mood disorders. Neuroimage (2008) 1.37
Selective reduction in amygdala volume in pediatric anxiety disorders: a voxel-based morphometry investigation. Biol Psychiatry (2005) 1.37
A longitudinal study of the effects of lithium treatment on prefrontal and subgenual prefrontal gray matter volume in treatment-responsive bipolar disorder patients. J Clin Psychiatry (2009) 1.33
Habenula volume in bipolar disorder and major depressive disorder: a high-resolution magnetic resonance imaging study. Biol Psychiatry (2010) 1.32
Global gene expression associated with hepatocarcinogenesis in adult male mice induced by in utero arsenic exposure. Environ Health Perspect (2006) 1.30
Reproducibility of prefrontal γ-aminobutyric acid measurements with J-edited spectroscopy. NMR Biomed (2011) 1.29
Distinct profiles of neurocognitive function in unmedicated unipolar depression and bipolar II depression. Biol Psychiatry (2007) 1.28
Keeping the body in mind: insula functional organization and functional connectivity integrate interoceptive, exteroceptive, and emotional awareness. Hum Brain Mapp (2012) 1.27
In vivo detection of gray and white matter differences in GABA concentration in the human brain. Neuroimage (2006) 1.27
Normal prefrontal gamma-aminobutyric acid levels in remitted depressed subjects determined by proton magnetic resonance spectroscopy. Biol Psychiatry (2005) 1.26
Measurement and automatic correction of high-order B0 inhomogeneity in the rat brain at 11.7 Tesla. Magn Reson Imaging (2004) 1.24
Perioperative reactivation of hepatitis B virus replication in patients undergoing partial hepatectomy for hepatocellular carcinoma. J Gastroenterol Hepatol (2012) 1.23
Serotonin transporter binding in bipolar disorder assessed using [11C]DASB and positron emission tomography. Biol Psychiatry (2006) 1.23
Localization of dysfunction in major depressive disorder: prefrontal cortex and amygdala. Biol Psychiatry (2010) 1.21
Selective effects of cholinergic modulation on task performance during selective attention. Neuropsychopharmacology (2007) 1.21
Effect of acamprosate on magnetic resonance spectroscopy measures of central glutamate in detoxified alcohol-dependent individuals: a randomized controlled experimental medicine study. Arch Gen Psychiatry (2010) 1.21
Neural correlates of rapid antidepressant response to ketamine in treatment-resistant unipolar depression: a preliminary positron emission tomography study. Biol Psychiatry (2013) 1.21
Neural circuitry and neuroplasticity in mood disorders: insights for novel therapeutic targets. NeuroRx (2006) 1.19
Widespread abnormality of the γ-aminobutyric acid-ergic system in Tourette syndrome. Brain (2012) 1.19
Altered brain serotonin 5-HT1A receptor binding after recovery from anorexia nervosa measured by positron emission tomography and [carbonyl11C]WAY-100635. Arch Gen Psychiatry (2005) 1.16
Dexamethasone increases expression and activity of multidrug resistance transporters at the rat blood-brain barrier. Am J Physiol Cell Physiol (2008) 1.16
Prefrontal cortical abnormalities in currently depressed versus currently remitted patients with major depressive disorder. Neuroimage (2010) 1.16
Amygdala volume in depressed patients with bipolar disorder assessed using high resolution 3T MRI: the impact of medication. Neuroimage (2009) 1.16
The effect of acute tryptophan depletion on the neural correlates of emotional processing in healthy volunteers. Neuropsychopharmacology (2007) 1.15
Automated subcortical segmentation using FIRST: test-retest reliability, interscanner reliability, and comparison to manual segmentation. Hum Brain Mapp (2012) 1.14
In vivo 13C magnetic resonance spectroscopy of human brain on a clinical 3 T scanner using [2-13C]glucose infusion and low-power stochastic decoupling. Magn Reson Med (2009) 1.14
Lateralization and gender differences in the dopaminergic response to unpredictable reward in the human ventral striatum. Eur J Neurosci (2011) 1.13
Scopolamine produces larger antidepressant and antianxiety effects in women than in men. Neuropsychopharmacology (2010) 1.13
Novel strategy for cerebral 13C MRS using very low RF power for proton decoupling. Magn Reson Med (2007) 1.13
Sustained low-grade pro-inflammatory state in unmedicated, remitted women with major depressive disorder as evidenced by elevated serum levels of the acute phase proteins C-reactive protein and serum amyloid A. Biol Psychiatry (2006) 1.13
Spatiotemporal dynamics of the brain at rest--exploring EEG microstates as electrophysiological signatures of BOLD resting state networks. Neuroimage (2012) 1.13
Regional cerebral glucose metabolic abnormalities in bipolar II depression. Biol Psychiatry (2006) 1.13
NF-kappaB-dependent cytokines in saliva and serum from patients with oral lichen planus: a study in an ethnic Chinese population. Cytokine (2008) 1.12
Tgif1 and Tgif2 regulate Nodal signaling and are required for gastrulation. Development (2010) 1.12
Comparative proteomics approach to screening of potential diagnostic and therapeutic targets for oral squamous cell carcinoma. Mol Cell Proteomics (2008) 1.11
New insights into the role of cortisol and the glucocorticoid receptor in severe depression. Biol Psychiatry (2002) 1.11
Neuroreceptor imaging in depression. Neurobiol Dis (2012) 1.11
5-HT1A receptor binding in temporal lobe epilepsy patients with and without major depression. Biol Psychiatry (2007) 1.09
Correlation between bocavirus infection and humoral response, and co-infection with other respiratory viruses in children with acute respiratory infection. J Clin Virol (2010) 1.09
Retroperitoneal liposarcoma: MR characteristics and pathological correlative analysis. Abdom Imaging (2007) 1.09
Single-shot two-echo technique for simultaneous measurement of GABA and creatine in the human brain in vivo. Magn Reson Med (2004) 1.08
Reduced posterior hippocampal volume in posttraumatic stress disorder. J Clin Psychiatry (2008) 1.08
Effects of a alpha 2C-adrenoreceptor gene polymorphism on neural responses to facial expressions in depression. Neuropsychopharmacology (2006) 1.08
Blood metallothionein transcript as a biomarker for metal sensitivity: low blood metallothionein transcripts in arsenicosis patients from Guizhou, China. Environ Health Perspect (2007) 1.04
Y-contacted high-performance n-type single-walled carbon nanotube field-effect transistors: scaling and comparison with Sc-contacted devices. Nano Lett (2009) 1.04
In vivo 1H-magnetic resonance spectroscopy study of the attentional networks in autism. Brain Res (2010) 1.03
Prefrontal cortical gamma-aminobutyric Acid levels in panic disorder determined by proton magnetic resonance spectroscopy. Biol Psychiatry (2008) 1.03
Genetic modulation of GABA levels in the anterior cingulate cortex by GAD1 and COMT. Neuropsychopharmacology (2010) 1.02
Effect of acute psychological stress on prefrontal GABA concentration determined by proton magnetic resonance spectroscopy. Am J Psychiatry (2010) 1.02
Spectral localization by imaging using multielement receiver coils. Magn Reson Med (2011) 1.02
Altered cerebral gamma-aminobutyric acid type A-benzodiazepine receptor binding in panic disorder determined by [11C]flumazenil positron emission tomography. Arch Gen Psychiatry (2008) 1.02